A new bronchodilating agent, procaterol, in preventing exercise-induced asthma.

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Exercise-induced asthma (EIA) is a common condition affecting individuals with asthma.
• Beta-2-adrenoceptor stimulants are frequently used to manage asthma symptoms.

Purpose of the Study:

• To evaluate the efficacy of procaterol, a selective beta-2-adrenoceptor agonist, in preventing EIA.
• To compare the effectiveness of procaterol with salbutamol and a placebo in asthmatic patients.

Main Methods:

• A randomized, placebo-controlled study involving 12 asthmatic patients with EIA.
• Patients underwent standardized treadmill exercise challenges after administration of procaterol (20 mcg), salbutamol (200 mcg), or placebo via metered aerosol.
• Lung function, specifically forced expiratory volume in the first second (FEV1), was measured at various time points before and after exercise.

Main Results:

• Both procaterol and salbutamol demonstrated mild bronchodilation 15 minutes post-administration, with salbutamol showing a statistically significant effect (p < 0.006) and procaterol showing a non-significant trend (+8%).
• Lung function indices showed a significant difference (p < 0.01) between the active drugs and placebo.
• No significant differences in efficacy were observed between procaterol and salbutamol in preventing EIA.

Conclusions:

• Procaterol is effective in preventing exercise-induced asthma.
• Procaterol demonstrates comparable efficacy to salbutamol in managing EIA.
• Procaterol represents a potentially valuable therapeutic option for patients suffering from exercise-induced asthma.